- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older · Male only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
Location Directory
Clinical trials in Indianapolis, Indiana
This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8617
Shown on this page
12
Current sort
Recently updated
Location scope
Indianapolis, IN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 889–900 of 8,617 matching trials in Indianapolis, IN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Thoracolumbar Spinal Fusion
- Interventions
- Not listed
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Minneapolis, Minnesota • Columbus, Ohio
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- ABBV-706, Topotecan, Lurbinectedin, Amrubicin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 32 more
- Conditions
- HIV -1 Infection
- Interventions
- GS-0415, GS-0415 Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami Lakes, Florida + 12 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
- Conditions
- Type 1 Diabetes (T1D)
- Interventions
- DailyDose
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 3 more
- Conditions
- Myotonic Dystrophy Type 1 (DM1)
- Interventions
- DYNE-101, Placebo
- Drug
- Lead sponsor
- Dyne Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 8
- States / cities
- Stanford, California • Gainesville, Florida • Indianapolis, Indiana + 5 more
- Conditions
- Surgical Residency, Workplace Culture, Mistreatment, Burnout
- Interventions
- Resource allocation to improve surgical learning environments
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Not listed
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Locally Advanced or Metastatic Malignant Solid Tumors
- Interventions
- enfortumab vedotin, pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Telisotuzumab Adizutecan
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 24
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 20 more
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
- Interventions
- Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 29 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more